TP53 and non-small cell lung carcinoma: Notably, it (50 μM) activates the E2F4 pathway in small cell lung cancer (NSCLC) [153], promotes mutant p53 degradation via autophagy (IC50 of 200 μM) [154], and triggers apoptosis through the TRPV6-calcium-calpain axis [155].